OVERVIEW
This policy documents the criteria and documentation requirements for immunoassay testing (i.e., qualitative testing, screening) and quantitative testing (i.e., confirmatory testing) drug toxicology tests.

MEDICAL CRITERIA
Not applicable

PRIOR AUTHORIZATION
Not applicable

POLICY STATEMENT
BlueCHiP for Medicare and Commercial Products
Immunoassay testing (i.e., qualitative testing, screening) and quantitative testing (i.e., confirmatory testing) urine drug toxicology tests are covered.

Medical records must document the medical necessity of billed services and must be made available to Blue Cross & Blue Shield of Rhode Island (BCBSRI) upon request. See the Background section of this policy for documentation requirements.

Qualitative testing is not eligible for reimbursement as described below:
- Testing as required for or as part of participation in a substance abuse program with an all-inclusive bundled rate
- Routine testing (i.e., testing at every visit)
- Testing ordered by or for third parties for the sole purpose of meeting the requirements of a third party

Quantitative testing is not eligible for reimbursement as described below:
- Routine quantitative drug testing (i.e., testing at each visit)
- Quantitative testing when qualitative testing is clinically appropriate and meets clinical needs
- Routine confirmatory testing in the absence of an unexpected positive finding or an unexpected negative finding
- Testing ordered by or for third parties for the sole purpose of meeting the requirements of a third party

In outpatient pain management and substance abuse treatment, hair drug testing and oral fluid drug testing are considered not medically necessary. The current published evidence does not permit conclusions on the impact of hair or oral fluid drug testing on clinical outcomes.

COVERAGE
Benefits may vary. Please refer to the appropriate Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for applicable laboratory benefits/coverage.
**BACKGROUND**

**Immunoassay Testing (i.e., Qualitative Testing, Screening)**

These tests can be performed either in a laboratory or at the point of service. Immunoassay tests are based on the principle of competitive binding and use antibodies to detect a particular drug or drug metabolite in a urine sample. With competitive binding, a fixed amount of a labeled drug is added to the urine sample, and the drug or metabolite in the sample competes with the labeled drug for binding sites on the antibody. The amount of labeled antigen that binds with the antibody is inversely proportional to the amount of the drug or metabolite in the sample.

Immunoassay tests vary in the type of compounds they can detect. Some detect specific drugs and may fail to recognize similarly structured drugs within the same class. Other immunoassays identify only classes of drugs and thus results cannot be used to determine which drug a patient is taking. For example, a positive result to an opiate immunoassay can be due to morphine or hydromorphone. The degree of cross-reactivity, i.e., an antibody’s reactivity with a compound other than the target of the test, varies widely among immunoassays.

Immunoassay findings are generally reported qualitatively as either positive (drug level above a prespecified threshold) or negative (drug level below a prespecified threshold). Raising or lowering the threshold thus changes the proportion of positive tests. A negative test is interpreted as a level below the threshold and does not necessarily mean that the drug or metabolite is absent.

Immunoassays generally have a rapid turnaround time, within minutes for onsite tests and 1 to 4 hours for laboratory-based tests.

Qualitative urine drug testing to verify compliance with treatment or identify disclosed drug use or abuse is considered medically necessary as part of a routine monitoring program. Qualitative urine drug testing is considered medically necessary under the following conditions:

- An individual is receiving treatment for chronic pain with prescription opioid or other potentially abused medications; or
- An individual is undergoing treatment for or monitoring for relapse of opioid addiction or substance abuse; or
- Abuse of non-prescribed medications or illegal substances is suspected; or
- An individual is beginning a pain management program or substance abuse recovery program.

Medical records must document the medical necessity of billed services.

**Specific Drug Identification (i.e., Quantitative Testing, Confirmatory Testing)**

Confirmatory tests are always performed in a laboratory. Gas chromatography/mass spectrometry (GC/MS) is considered to be the criterion standard for confirmatory testing. This technique involves using GC to separate the analytes in a specimen and MS to identify the specific molecular structures of the drug and its metabolites. The tests are able to quantify the amount of drug or metabolite present in the urine sample. Quantitative tests can be used to confirm the presence of a specific drug identified by a screening test and can identify drugs that cannot be isolated by currently available immunoassays. Results are reported as the specific levels of substances detected in the urine. GC/MS generally requires specification of the drug or drugs to be identified. Alternatively, “broad spectrum screens” can be conducted. There is a several day turnaround time for GC/MS testing.

An issue with both types of UDT is the possibility of sample tampering to mask the presence of illegal drugs. A variety of products and techniques are available to patients, and can be as simple as drinking a large amount of water to dilute the sample. There are also commercial dilution and cleaning products, additives, and urine substitutes. Some of these techniques can be detected by visual inspection of the sample, e.g., color, or by onsite testing of sample characteristics including urine temperature, creatinine concentration, and specific gravity.
In addition, correct interpretation of urine drug testing (UDT) results is very important. Knowledge of drug metabolites is essential for accurate interpretation. Accurate interpretation of test results also requires knowledge of the drug manufacturing process. For example, due to manufacturing impurities, a small amount of hydrocodone may be present in urine samples from patients prescribed oxycodone. Thus, it would be acceptable to have this degree of hydrocodone if high amounts of oxycodone were also present.

There are various approaches to incorporating urine drug screening (UDS) into pain management and substance abuse treatment settings. Most commonly, patients undergo UDS before beginning treatment to verify current drug use. Some clinicians believe that UDS should be routinely used to establish baseline information about substance use, but the optimal frequency and interval of testing remains uncertain. A universal approach to screening may uncover more inappropriate use and may reduce patients’ sense that testing is being performed due to a lack of trust. However, routine universal screening may place an unnecessary burden on the healthcare system and on the doctor-patient relationship. An alternative approach is selective testing of patients who are judged to be at increased risk for drug misuse.

Existing protocols vary for use of qualitative versus quantitative tests. Some of these involve conducting routine confirmation of positive qualitative tests with quantitative testing. Others use selective confirmation of positive qualitative tests, such as when an unexpected immunoassay result is not adequately explained by the patient. There is also a mixed approach, with routine confirmation of qualitative tests only for drugs with poor-performing immunoassays.

**Guidance Regarding Quantitative, i.e., Confirmatory Testing**

Specific situations for quantitative drug testing may include, but are not limited to the following:

- Unexpected positive test inadequately explained by the patient
- Unexpected negative test (suspected medication diversion)
- Need for quantitative levels to compare with established benchmarks for clinical decision making

Quantitative or confirmatory testing must be ordered on an individual basis by a medical provider directly caring for a member at the time of order and may not be ordered from “standing” orders, i.e., orders that provide for routine testing. Quantitative testing must be ordered with an indication of the specific drug being confirmed, not as a comprehensive confirmatory panel.

According to Medicare instructions, drug testing providers performing validity testing on urine specimens utilized for drug testing should not separately bill the validity testing. For example, if a laboratory performs a urinary pH, specific gravity, creatinine, nitrates, oxidants, or other tests to confirm that a urine specimen is not adulterated, this testing is not separately billed. Testing to confirm that a urine specimen is unadulterated is an internal control process that is not separately reportable.

The evidence for oral fluid and hair drug testing in individuals who have chronic pain treated with opioids or who have a drug addiction and are in substance abuse treatment includes several diagnostic accuracy studies. Relevant outcomes include test and validity, health status measures, and resource utilization. Two studies of pain management patients and 1 of substance abuse treatment patients have evaluated diagnostic accuracy of oral fluid testing compared with urine testing. The studies reported sensitivities in the range of 75% to 100%, with variability in the sensitivity by type of drug. The reported specificities are higher, generally greater than 90% across different drugs. No studies were identified on the clinical utility of oral fluid testing in pain management or substance abuse treatment. Hair testing cannot detect recent drug use (ie, in the past few days) and thus has limited applicability to pain management or substance abuse treatment settings except, perhaps, for initial intake. There are no studies comparing the diagnostic accuracy of hair testing compared to urine testing in either of these settings. However, 1 relatively small study tested the hair and urine of known drug users recruited from a psychiatric clinic. The study looked for drug use over the past several months rather than the shorter timeframe generally needed in pain management or drug treatment settings. No studies were identified on the clinical utility of hair testing in pain management or substance abuse treatment.
The current published evidence does not permit conclusions on the impact of hair or oral fluid drug testing on clinical outcomes.

**Regulatory Status**
GC/MS tests and some immunoassays are performed in laboratory settings. Clinical laboratories may develop and validate in house (i.e., laboratory-developed) tests and market them as a service. Laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Act (CLIA).

A CLIA waiver is available for use of certain point-of-care immunoassays. Tests eligible for a CLIA waiver are those considered to be simple, with low risk of error and low potential for harm. The U.S. Food and Drug Administration (FDA) is tasked with approving manufacturers’ applications for test system waivers. There are commercially available CLIA-waived tests for drugs such as cocaine, methadone, morphine/opiates, and oxycodone.

**CODING**
BlueCHiP for Medicare and Commercial Products

Note: It is incorrect to bill creatinine, pH, specific gravity, aldehyde, chromate, oxidase, or any other test for specimen validity testing in addition to the drug testing codes. The code descriptions for G0477-G0483 include sample validation, if performed.

The following HCPCS codes effective January 1, 2016 are covered when payment guidelines are met:

- G0477
- G0478
- G0479
- G0480
- G0481
- G0482
- G0483

The following CPT codes should not be used. Claims should be filed with one of the above HCPCS G codes.

- CPT range 80300 through 80377
- 80184 83992

The following codes are discontinued effective December 31, 2015:

- G0431
- G0434
- G6030 - G6058
- 82541 83788

**RELATED POLICIES**
None

**PUBLISHED**
Provider Update, October 2016
Provider Update, March 2016
Provider Update, July 2015
Provider Update, November 2013
Provider Update, June 2011
Provider Update, July 2008

**REFERENCES**


